These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 24603161

  • 1. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H, Xie J, Chen L, Wang T, Sun J, Zhao Y, Dong Y.
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [Abstract] [Full Text] [Related]

  • 2. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H.
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation.
    Cojutti P, Maximova N, Crichiutti G, Isola M, Pea F.
    J Antimicrob Chemother; 2015 Jan; 70(1):198-206. PubMed ID: 25182066
    [Abstract] [Full Text] [Related]

  • 4. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A.
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients.
    Yagi T, Naito T, Doi M, Nagura O, Yamada T, Maekawa M, Sato S, Kawakami J.
    Int J Antimicrob Agents; 2013 Oct; 42(4):329-34. PubMed ID: 23988716
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
    Boak LM, Li J, Rayner CR, Nation RL.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic/pharmacodynamic research on three different infusion time regimens of linezolid in healthy Chinese volunteers.
    Cai Y, Bai N, Liu X, Liang B, Wang J, Wang R.
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):765-71. PubMed ID: 26227096
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients.
    Dong H, Xie J, Wang T, Chen L, Zeng X, Sun J, Wang X, Dong Y.
    Int J Antimicrob Agents; 2016 Sep; 48(3):259-64. PubMed ID: 27474469
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
    Lodise TP, Bosso J, Kelly C, Williams PJ, Lane JR, Huang DB.
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133566
    [Abstract] [Full Text] [Related]

  • 11. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL, Kiffer CR, Mendes CM, Nicolau DP.
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [Abstract] [Full Text] [Related]

  • 13. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y.
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [Abstract] [Full Text] [Related]

  • 14. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H, Martín-Suárez A, Lanao JM.
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [Abstract] [Full Text] [Related]

  • 15. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
    Andes D, van Ogtrop ML, Peng J, Craig WA.
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
    [Abstract] [Full Text] [Related]

  • 16. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM, Schmidt S, Zhuang L, Rand K, Derendorf H.
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [Abstract] [Full Text] [Related]

  • 17. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.
    Luque S, Grau S, Alvarez-Lerma F, Ferrández O, Campillo N, Horcajada JP, Basas M, Lipman J, Roberts JA.
    Int J Antimicrob Agents; 2014 Nov; 44(5):409-15. PubMed ID: 25216547
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
    Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, Tyrrell KL, Goldstein EJ.
    Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
    [Abstract] [Full Text] [Related]

  • 19. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
    Fernández de Gatta Mdel M, Santos Buelga D, Sánchez Navarro A, Dominguez-Gil A, García MJ.
    Clin Pharmacokinet; 2009 Mar; 48(4):273-80. PubMed ID: 19492872
    [Abstract] [Full Text] [Related]

  • 20. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics.
    Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y.
    J Infect Chemother; 2015 Jan; 21(1):70-3. PubMed ID: 25305808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.